Northland Securities Expects Stronger Earnings for Nephros

Nephros Inc. (NASDAQ:NEPH) – Northland Securities increased their FY2026 earnings per share estimates for Nephros in a research note issued on Friday, November 6th. Northland Securities analyst B. Brooks now expects that the company will post earnings per share of $0.18 for the year, up from their prior forecast of $0.15. Northland Securities has a “Market Perform” rating and a $4.00 price target on the stock. The consensus estimate for Nephros’ current full-year earnings is $0.18 per share. Northland Securities also issued estimates for Nephros’ Q3 2027 earnings at $0.07 EPS and FY2027 earnings at $0.32 EPS.

Nephros (NASDAQ:NEPH) last issued its quarterly earnings data on Thursday, November 5th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. Nephros had a net margin of 8.86% and a return on equity of 11.55%. The business had revenue of $5.62 million for the quarter, compared to the consensus estimate of $5.49 million.

Several other equities analysts have also recently issued reports on the stock. Benchmark reiterated a “speculative buy” rating on shares of Nephros in a research report on Tuesday, August 18th. Zacks Research upgraded shares of Nephros from a “hold” rating to a “strong-buy” rating in a report on Friday, November 6th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Nephros in a research report on Friday, October 30th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $4.00.

Nephros Trading Up 5.0%

Shares of NEPH opened at $3.15 on Monday. The firm’s 50-day moving average price is $3.74 and its 200-day moving average price is $3.63. The firm has a market capitalization of $34.24 million, a price-to-earnings ratio of 17.50 and a beta of 1.76. Nephros has a 1-year low of $2.66 and a 1-year high of $6.42.

Institutional Trading of Nephros

A number of institutional investors and hedge funds have recently bought and sold shares of NEPH. Navellier & Associates Inc. raised its holdings in Nephros by 179.6% in the second quarter. Navellier & Associates Inc. now owns 53,479 shares of the company’s stock worth $191,000 after buying an additional 34,353 shares during the last quarter. De Lisle Partners LLP purchased a new stake in shares of Nephros during the second quarter valued at approximately $62,000. Bard Associates Inc. purchased a new stake in shares of Nephros during the second quarter valued at approximately $421,000. BlackRock Inc. bought a new stake in shares of Nephros during the second quarter valued at approximately $67,000. Finally, Cornerstone Capital Inc. bought a new stake in shares of Nephros during the second quarter valued at approximately $459,000. 41.10% of the stock is currently owned by institutional investors.

About Nephros

Nephros, Inc. is a medical device company that develops and sells filtration products designed to improve water quality and reduce the risk of waterborne contamination. Its technologies are based primarily on ultrafiltration membranes that remove bacteria, viruses, endotoxins, cysts and other impurities from water. The company serves the healthcare market with filtration systems for hemodialysis and infection-control applications. Its products are designed for use in hospitals, dialysis centers and other healthcare facilities where purified water is important for patient care and clinical operations.